Cellectis SA (NASDAQ:CLLS) shares saw unusually-high trading volume on Tuesday . Approximately 178,055 shares were traded during trading, an increase of 107% from the previous session’s volume of 85,983 shares.The stock last traded at $26.67 and had previously closed at $26.65.

CLLS has been the subject of a number of research analyst reports. Piper Jaffray Cos. reissued a “buy” rating on shares of Cellectis SA in a research report on Sunday, May 8th. Zacks Investment Research downgraded shares of Cellectis SA from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Cellectis SA in a research report on Tuesday, May 31st. Finally, Jefferies Group reissued a “buy” rating on shares of Cellectis SA in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $43.60.

The stock’s 50 day moving average is $26.54 and its 200 day moving average is $27.19. The stock’s market capitalization is $945.87 million.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.